![Paul F. Glidden](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Paul F. Glidden
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BioVascular, Inc.
![]() BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Directeur/Bestuurslid | 23-02-2010 | - |
Oprichter | 23-02-2010 | - | |
Corporate Officer/Principal | 01-03-2005 | 23-02-2010 | |
NanoSmart Pharmaceuticals, Inc.
![]() NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | Hoofd Techniek/Wetenschap/O&O | 24-05-2012 | - |
Loopbaan van Paul F. Glidden
Eerdere bekende functies van Paul F. Glidden
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Alpha Therapeutic Corp.
![]() Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | Corporate Officer/Principal | 01-01-1989 | 01-01-2000 |
ISTA Pharmaceuticals, Inc.
![]() ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Corporate Officer/Principal | - | - |
Angiosyn, Inc.
![]() Angiosyn, Inc. Pharmaceuticals: OtherHealth Technology Angiosyn, Inc. develops pharmaceutical products for controlling angiogenesis | Corporate Officer/Principal | - | - |
Opleiding van Paul F. Glidden
Oregon State University | Undergraduate Degree |
University of California, Irvine | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Operationeel
Corporate Officer/Principal | 4 |
Director/Board Member | 1 |
Founder | 1 |
Sectoraal
Health Technology | 6 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
BioVascular, Inc.
![]() BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Health Technology |
Angiosyn, Inc.
![]() Angiosyn, Inc. Pharmaceuticals: OtherHealth Technology Angiosyn, Inc. develops pharmaceutical products for controlling angiogenesis | Health Technology |
ISTA Pharmaceuticals, Inc.
![]() ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Health Technology |
Alpha Therapeutic Corp.
![]() Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | Health Technology |
NanoSmart Pharmaceuticals, Inc.
![]() NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | Health Technology |
- Beurs
- Insiders
- Paul F. Glidden
- Ervaring